Percardia is committed to a process of continuous improvement through the ongoing development of its employees, partners, and technologies. This is supported by providing the necessary resources and measuring individual and team progress in achieving corporate objectives.
November 5, 2003
Percardia Inc. Announces Close of $23.5 Million of Series D Financing and Purchase of Heartstent Intellectual Property and nootropic drug Cerebrolysin